ArticleBMJ open2026
Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCoronary artery bypass grafting (CABG) is the main method to improve myocardial ischaemia in patients with complex coronary artery stenosis. Whereas, patients with diffuse coronary artery disease (DCAD) have a high incidence of perioperative myocardial infarction (PMI) and long-term major adverse cardiovascular and cerebrovascular events (MACCEs) after CABG. The coronary microcalcification activity reflected by sodium [ METHODS AND ANALYSIS: The COL-CABG trial is a single-centre, prospective, randomised, open-label, blinded-endpoint trial conducted at Beijing Anzhen Hospital, Capital Medical University. The study will prospectively enrol 108 DCAD patients with a tissue-to-background ratio (TBR) >3.6 at Beijing Anzhen Hospital from July 2026 to June 2028, and all patients are planned to undergo CABG. The patients will be randomly assigned (1:1) to (1) the colchicine group and (2) the control group. The primary endpoint is defined as the changes in coronary microcalcification activity (ΔTBR=TBR (baseline)-TBR (90 days)) at 90 days after CABG in comparison with pre-CABG. Secondary clinical outcomes include PMI within 7 days after CABG and MACCEs within 90 days after CABG. MACCEs include all-cause death, cardiogenic shock, spontaneous myocardial infarction occurring after postoperative day 7, stroke and repeat coronary revascularisation. These clinical outcomes will be interpreted as exploratory and hypothesis-generating. ETHICS AND DISSEMINATION: This study has been approved by the Institutional Review Board of Beijing Anzhen Hospital, Capital Medical University (approval number: 2025202x). Written informed consent will be obtained from all participants. The results will be disseminated through peer-reviewed publications and scientific conference presentations. TRIAL REGISTRATION NUMBER: ChiCTR2500111659.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.